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Abstract: We developed a screening procedure to identify ligands from a phage display 
random peptide library that are selective for circulating bone marrow derived cells homing 
to angiogenic tumors. Panning the library on blood outgrowth endothelial cell suspension 
in vitro followed by in vivo selection based on homing of bone marrow-bound phage to 
angiogenic tumors, yielded the peptide QFPPKLTNNSML. Upon intravenous injection 
phage displaying this peptide homed to Lewis lung carcinoma (LLC) tumors in vivo 
whereas control phage did not localize to tumor tissue. Phage carrying the 
QFPPKLTNNSML peptide labeled with 64Cu radionuclide when administered 
intravenously into a tumor bearing mouse was detected noninvasively with positron 
emission tomography (PET) around the tumor. These proof-of-principle experiments 
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demonstrate the ability of the QFPPKLTNNSML peptide to deliver payload (radiolabeled 
phage conjugates) in vivo to sites of ongoing angiogenesis and point to its potential clinical 
utility in a variety of physiologic and pathologic processes where neovascular growth is a 
critical component. 
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The discovery and development of new cancer therapeutic and diagnostic compounds have 
traditionally relied on (i) isolation from natural sources, e.g., bioactive peptides, (ii) screening of 
chemical libraries, (iii) computer-based rational design, and (iv) antibody engineering [1]. Phage 
display peptide libraries provide an alternative source to acquire unique peptide ligands for various 
cancer-related disease targets. Phage display technology holds great promise to advance cancer 
diagnosis and treatment. Although numerous peptides have been discovered through screening 
combinatorial phage libraries only a small subset consist of cancer targeting peptides [2,3]. This is 
most likely associated with the convoluted processes involved in tumor development and the lack of 
well-defined tumor markers. Therefore new approaches for selection of tumor targeting peptides from 
phage libraries informed by knowledge of tumor biology are needed.  
Angiogenesis is considered to play a major role for the growth and dissemination of malignant 
tumors [4]. Tumors form new blood vessels either from pre-existing mature ones or from de novo by 
recruiting circulating endothelial and hematopoietic precursor cells [5]. Stromal cells of bone marrow 
(BM) origin have been identified in the vasculature of several pre-clinical models [6-8]. Importantly, 
circulating endothelial precursors have been shown to control the angiogenic switch in mouse lung 
metastasis [9]. In humans, BM-derived endothelial cells have been detected in patients with multiple 
myeloma [10], primary breast cancer [11], non-small cell lung cancer [12], and malignant gliomas 
[13]. Hematopoietic cells have also been shown to home to tumor tissue. Recent evidence indicates 
that chemokines such as vascular endothelial growth factor (VEGF) promote co-mobilization of 
circulating endothelial and hematopoietic precursor cells to the tumor vascular bed where they 
contribute to neovessel formation [14]. 
As bone marrow derived cells home to tumors, we hypothesized that peptides binding to these cells 
may be of interest as tools for the specific delivery of diagnostic reagents and anticancer therapeutic 
compounds. Thus in this study we set to identify peptide ligands from a phage display library that 
specifically recognize cell populations of  BM origin recruited to tumors and to characterize their 
tumor homing ability in vivo. Panning the library using a novel combined in vitro and in vivo selection 
protocol yielded the peptide QFPPKLTNNSML. We demonstrated the ability of the 
QFPPKLTNNSML peptide to deliver payload (radiolabeled phage conjugates) to sites of ongoing 
angiogenesis in a subcutaneously implanted Lewis lung carcinoma model. To the best of our 




knowledge this is the first study reporting the use of phage display technology to target tumors through 
circulating cells. 
2. Results and Discussion  
2.1. Peptide library screening 
During development, hematopoietic and vascular endothelial progenitors originate from a common 
precursor cell, the hemangioblast, and share several phenotypic characteristics [15]. Here we exploit 
this shared phenotype and use human blood outgrowth endothelial cells (HBOEC) cultured from 
peripheral blood mononuclear cells to enrich the phage library before panning on BM cells. This will 
allow for the discovery of peptides that specifically recognize molecular markers expressed both by 
endothelial precursors and distinct BM sub-population(s). To distinguish the cell population(s) of BM 
origin capable of homing to tumors, we introduced a functional feature in our screen: only phage 
carried by BM cells to angiogenic tumors were propagated and used for subsequent enrichment. Figure 
1 depicts a schematic of our selection procedures.  
 
Figure 1. Selection of tumor-associated phage via a combination of in vitro and in vivo 
biopanning protocols. (A) A random 12-mer peptide library was pre-selected in vitro on 
HUVEC (one round of negative selection) and on HBOEC (three rounds of positive 
selection) which resulted in an enriched phage pool, designated as mini-library. The mini-
library was used for in vivo panning of tumor-associated phage employing two distinct 
selection schemes. (B) The mini-library was injected i.v. in a LLC tumor bearing mouse. 
Phage were allowed to circulate for 2 hours and the mouse was perfused with PBS. Then 
the tumor was excised, the tumor-bound phage pool was amplified in E. Coli, and used for 
another round of biopanning. Total of three in vivo selection cycles were conducted 
utilizing free phage. (C) Freshly isolated bone marrow (BM) cells were labeled with the 
mini-library. BM-bound phage were injected i.v. into the tail vein of a LLC tumor bearing 
mouse. After 2 hours of circulation the mouse was perfused with PBS. The phage were 
rescued from the tumor, amplified, and used to label BM cells for subsequent enrichment 
cycles. Three rounds of in vivo functional selection were performed using BM-bound phage.  
 
 




Figure 2. Homing efficiency of the phage pool from each selection cycle, calculated as the 
ratio of output phage titer to input phage titer multiplied by 100. Using BM cells to deliver 
phage to tumors improves the efficiency of the selection procedure in the range of 50-fold. 
The bars show standard error of the mean (s.e.m.) from plating quadruplicates. P values 
were calculated by Student’s t-test and were considered statistically significant at P < 0.05. 
 
After one round of negative selection on human umbilical vein endothelial cells (HUVEC) to 
deplete the library of clones that bind to common cell surface receptors and three rounds of positive 
selection on HBOEC in vitro, we generated a mini-library of enriched phage pool for further 
downstream biopanning (Figure 1A). We utilized two distinct in vivo selection protocols in parallel 
and compared the results: (i) The mini-library was either directly injected intravenously into a mouse 
bearing subcutaneously implanted LLC tumor (Figure 1B) or (ii) A functional step was employed that 
consisted of administering BM-bound phage into a mouse bearing subcutaneously implanted LLC 
tumor (Figure 1C). To enable the latter protocol we isolated murine BM cells from femoral and tibial 
bones and labeled the cell suspension with the mini-library. Free phage or BM-bound phage were 
allowed to circulate for 2 hours. Then the mice were perfused through the heart with PBS and the 
tumors were harvested. Tumor-associated phage pool from each protocol was propagated separately in 
E. Coli, and used in subsequent enrichment cycles. The efficiency of each cycle was quantified as the 
ratio of the output phage titer to input phage titer multiplied by 100. As seen from Figure 2 using BM 
cells to deliver phage to tumors improves the efficiency of the selection procedure dramatically.   
To rule out library phage binding to the Matrigel matrix which is a component of the implanted 
tumors, we used a Matrigel plug without LLC cells as a control. Matrigel was injected symmetrically 
to the LLC tumor in the same animal used for the last round of biopanning. After tumors and the 
control plugs were excised and bound phage recovered, fifty randomly chosen phage clones resulting 
from each protocol both for the tumors and the control plugs (200 phage clones in total) were plaque 
purified and sequenced. Figure 3 presents the phage inserts sequencing distribution profiles for both 
selection procedures for the tumors and the control plugs. The biopanning protocol with free phage 
does not produce a noticeable enrichment after three rounds of in vivo selection.  In contrast to what is 
seen with free phage, when BM cells are utilized in the panning procedure a dominant phage clone, 
L12, emerges. The sequencing results in Figure 3 are in agreement with the homing efficiency findings 
in Figures 2, supporting the observation that the selection procedure based on specific functional 
attributes, i.e., the target is unique to cancer as these BM-derived circulating cells have the natural 




ability to localize to tumors, has notable efficiency and produces a phage clone that displays a 
preferentially enriched amino acid sequence. Regarding specificity, the dominant clone, L12, is 
recovered from the Matrigel plug with equal frequency to the tumor in the free phage screen, and with 
highest frequency (8 out of 50 sequenced clones) for the plug in the BM-bound phage screen. 
However, as shown in Figure 3, we observed that the overall amount of phage homing to tumors in 
both screens is much higher compared to the amount of phage localizing to the Matrigel controls, i.e., 
in order to obtain 50 phage clones for sequencing we processed larger amounts of control plugs 
compared to tumors. Thus we conclude that the selection protocols utilized here are remarkably 
specific as minimal background phage accumulation to the control plugs has been detected. 
 
Figure 3. Frequency of sequenced peptide ligands selected either by panning with free 
phage (A) or by panning using bone marrow-bound phage (B). After three rounds of in 
vivo selection, fifty phage clones homing to tumors and to Matrigel controls from each 
protocol were randomly chosen for sequencing. Frequency refers to the number of times 
each phage was isolated out of the total number of phage sequenced. In vivo selection with 
free phage produces no apparent enrichment of particular clones. By stark contrast, three 
rounds of in vivo functional selection, using BM cells to direct the phage pool to the tumor 
site, are sufficient to identify a dominant amino acid sequence. The inserts in both panels 

















2.2. Peptide sequence analysis 
The peptide sequences that appeared with the highest frequency in the sequenced phage pool are 
listed in Table 1. Two of the peptides, L12 and L34, were encountered in a previous study that utilized 
in vitro selection protocol for identification of HBOEC-specific peptides [16]. Although these findings 
confirm our initial hypothesis of shared phenotypic expression between outgrowth endothelial 




precursors and circulating bone marrow derived cells, neither L12 nor L34 peptide was enriched in the 
HBOEC-specific phage pool (1 occurrence for each peptide in a pool of 40 sequenced peptides). 
Furthermore, we searched MimoDB, the newly developed repository of peptides derived by screening 
of phage display libraries [17], and found that none of the peptides listed in Table 1 has been identified 
to bind to other targets. We selected the phage clone with the highest frequency of occurrence for 
further characterization. This phage expresses the peptide sequence QFPPKLTNNSML, denoted also 
as QFP-peptide.  
 
Table 1. Peptides identified with the highest frequency from the sequenced phage pool. 











Prompted by observations from other studies that peptides isolated by phage display are often 
functionally active and bind to sites of protein-protein interactions [18,19], we searched the non-
redundant protein database (nr) at NCBI using the BLASTp tool to find potential homologies to the 
QFP-peptide [20]. BLASTp alignments with algorithm parameters adjusted to identify short and nearly 
exact matches, revealed a number of similarities to proteins with cell membrane or extracellular 
function (see Table 2). Human immunodeficiency virus type 1 enhancer binding protein also 
recognized as major histocompatibility complex binding protein 1 is known to mediate immune 
evasion and promote viral persistence by down regulating major histocompatibility complex in 
peripheral blood mononuclear cells [21]. Serine protease 55 (PRSS55) is a member of a group of 
membrane anchored chemotrypsin (S1)-like serine proteases that have a role in normal homeostasis as 
well as in pathology of diseases such as cancer. Homology with the QFP-peptide occurs at the 
hydrophobic part of the C-terminus of PRSS55 which provides basis for cell membrane anchoring 
[22]. Cubilin (3623 aa protein) acts as a receptor for intrinsic factor-vitamin B12 (cobaltamin) 
complexes. Limited tissue expression of cubilin and its putative importance for cell cancer growth 
have motivated studies to explore cubilin as a new target for the delivery of organometallic B12-based 
conjugates for cancer diagnosis and treatment [23]. Finally, we have found through analysis for 
conserved domains that the KLTNNS region of the integrin β2 aligns with the QFP-peptide [24]. Βeta-
2 integrins are known to play an important role in the leukocyte-endothelial interactions [25]. Recent 
studies indicate that circulating tumor cells bind in increased numbers to cytokine activated 
endothelium in a process reminiscent with of leukocyte-endothelial adhesion [26]. Of note, the 
extracellular matrix components of Matrigel in the LLC tumors may provide ligands for β2 integrin 
mediated interactions thus potentially causing off-specificity binding. Whether the QFP-peptide 
actually participates in the functional interactions identified through bioinformatics analysis and the 
specific molecular mechanisms involved remains to be further investigated. 
 




Table 2. Identified sequence homologies to the QFPPKLTNNSML peptide obtained by 
searching the non-redundant (nr) NCBI protein database performing local sequence 
alignment. The underlined amino acids correspond to exact alignment of the protein 
sequences with the new peptide. The numbering on both ends of the sequences indicates 
the region where homology occurs.  
Protein Sequence Protein Name Accession 
233—PPKLKNSSM –241 Human Immunodeficiency Virus  
Type 1 Enhancer Binding Protein 
AAI 40817.1 
227—PKLTKN-ML –234 Serine Protease 55 (PRSS55) NP_001183949 
3118—PPNVKSSNNSML – 3129 Cubilin 
(intrinsic factor cobalamin receptor) 
EAN 86221.1 
187—KLTNNS –192 Integrin 　2  EAX 09383 
 
2.3. Characterization of QFP-phage clone binding to LLC tumors by plaque assay 
 
QFP-phage was grown to a high titer and used for labeling of freshly isolated BM cells. Phage-BM 
cell complexes were re-suspended in PBS and injected intravenously into LLC tumor bearing mice  
(n = 3). Experiments with control non-targeted phage were performed in parallel. After 2 hours of 
circulation blood was collected, the mouse perfused with PBS, and heart, tumor and liver harvested. 
The amount of phage in blood and each tissue was determined by plaque assay by counting the number 
of infectious phage particles. As shown in Figure 4, liver and blood retained the most phage and heart 
retained the least at 2 hours post-injection. The amount of QFP-phage in the tumor was statistically 
higher than the amount of non-targeted phage. Furthermore, tumor-to-liver and tumor-to-blood ratio 
were significantly higher for QFP-phage compared to the control. 
Figure 4. (A) Localization of QFP- and control phage to LLC tumors, heart, liver and 
blood at 2 hours post-injection of BM cells labeled with phage. Statistically higher amount 
of QFP-phage was detected in LLC compared to a control insertless phage. (B) Tumor-to-
blood and tumor-to-liver ratio for QFP- and control phage. Both ratios are statistically 
higher for QFP-phage compared to the control (P < 0.05). 




2.4. Noninvasive quantitation of in vivo peptide binding to LLC tumors by positron emission 
tomography 
Next, we explored the ability of the QFPPKLTNNSML peptide to deliver molecular cargo to sites 
of ongoing angiogenesis by noninvasive positron emission tomography (PET) imaging. For this 
purpose we developed a labeling platform employing the phage that displays the QFPPKLTNNSML 
peptide as a molecularly targeted imaging agent. Using phage as imaging probes and biological 
nanoparticles in targeting tumors offers an immediate advantage: phage can be covalently attached to 
numerous labels while simultaneously expressing multiple copies of the tumor-avid peptide [27]. In 
this study we labeled QFP-phage with 64Cu radionuclide via the macrocyclic chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetra acetic acid (DOTA). First, we functionalized the phage particle 
conducting a coupling chemical reaction between amino groups exposed on the phage surface and the 
bifunctional p-SCN-Bn-DOTA derivative as illustrated in Figure 5. In a second step we performed a 
labeling reaction to attach the 64Cu2+ radiometal to the DOTA-phage-QFP construct. 64Cu radiolabeled 
insertless phage conjugates and 64Cu-DOTA complexes were prepared to serve as controls. The 
chemical modification of the phage surface did not affect cellular binding or phage infectivity (results 
not shown). Thus phage retained target affinity and biological activity on labeling. 
Figure 5. Design and synthesis of M13 phage-based molecularly targeted imaging 
platform for noninvasive assessment and visualization of in vivo peptide binding by 
positron emission tomography (PET). (A) M13 bacteriophage is a long filamentous particle 
approx. 6 nm in diameter and 900 nm in length. The viral genome is encapsulated in 
approx. 2700 copies of the major coat protein pVIII. The minor coat protein pIII that caps 
the particle is engineered to display five copies of a tumor-avid QFPPKLTNNSML 
peptide. Five lysine groups (Lys 8, 40, 43, 44, 48) and one N-terminal amino group (Ala 1) 
on each pVIII subunit are available for chemical modification [28]. (B) Bifunctional p-
SCN-Bn-DOTA derivative is added to a 1 × 1011 pfu phage in conjugation buffer at  
pH = 9. The chemical reaction for covalent attachment of DOTA to the phage surface is 
carried out for 16 hours at 35 °C. (C) The 64Cu2+ radiometal is attached through 
coordinative binding to the DOTA-phage construct for 50 min at 50 °C. 
 




We utilized PET imaging to quantitate noninvasively the ability of the 64Cu labeled QFP-phage to 
bind in vivo to its target in angiogenic highly vascularized subcutaneously implanted LLC tumors  
(n = 3). The labeled phage were injected i.v. into a tumor bearing mouse and the localization of 64Cu-
DOTA-phage -QFP radiotracer visualized. The distribution of two control radiotracers, 64Cu-DOTA 
and 64Cu-DOTA- phage with no peptide insert, was examined in parallel. Representative decay 
corrected coronal PET images at 18 hours post-injection are shown in Figure 6A. 64Cu-DOTA-phage -
QFP was able to bind its target in vivo thus producing an excellent tumor uptake and contrast in the 
tumor tissue while the control phage showed little to no accumulation in the tumor. 64Cu-DOTA 
complex revealed a completely different pattern of in vivo distribution confirming that the signal from 
the 64Cu-DOTA-phage -QFP is due to the 64Cu-DOTA covalently bound in a stable manner to the 
QFP-phage vector. Figures 6B and C quantify the standard uptake values (SUV) for the tumor and 
liver, respectively. 64Cu-DOTA-phage –QFP has a statistically higher standard tumor uptake value 
compared to both controls. 
Figure 6. (A) Representative coronal microPET images of mice bearing LLC tumors. 
Images were acquired 18 hours post-injection of 800 μCi of 64Cu-DOTA, 64Cu-DOTA-
control non-targeted phage, or 64Cu-DOTA-QFP-targeted phage. (B) Standard uptake 
values calculated from the coronal PET images in tumor (mean ± s.e.m., n = 3). (C) 
Standard uptake values calculated from the coronal PET images in liver (mean ± s.e.m.,  
n = 3). P values were determined by Student’s t-test and were considered statistically 
significant at P < 0.05. 




As seen in Figure 6 there is a capture of radiolabeled phage by the liver. These observations are 
consistent with the findings from the phage distribution experiments presented in Figure 4. Both QFP-
phage and the insertless control phage are taken up and catabolized by the liver. The fact that liver 
localization is independent of the presence of a peptide on the surface of the phage clearly indicates 
that liver uptake is a property of the phage, and not the peptide carried by the phage. Taken together 
our imaging results reveal that the QFPPKLTNNSML peptide identified by in vivo functional selection 
from a phage display peptide library can deliver molecular cargo to angiogenic tumors.  
Possible limitations may be associated with the synthetic approach employed in this study, i.e., the 
chemical modification of primary amino groups exposed on the surface of the phage particle. The 
isothiocyanate of the DOTA reagent can presumably form a thiourea with the side chain primary 
amine of the lysine residue of the QFP-peptide thus potentially reducing the effective binding affinity 
of the targeting moiety. This in turn may affect the biodistribution profile of the radioconjugate. 
Detailed MALDI-TOF MS analysis is currently underway to further characterize the reaction products 
and identify modification sites. Alternative bioconjugation methods such as covalent attachment of 
DOTA to the carboxylic reactive groups of the aspartic and glutamic acid residues or to the phenol 
groups of the tyrosine on the phage surface are warranted in future studies. 
The ability to target vasculature for imaging or drug delivery purposes has been an elusive goal. 
Peptide sequences harnessing endogenous cellular machinery to accomplish this goal represent a new 
targeting approach that is likely to escape immune surveillance. The studies reported here provide 
proof-of-principle for this approach. Subsequent refinements using modified peptide sequences 
coupled to imaging agents and/or biologically active molecules may have clinical utility in a variety of 
physiologic and pathologic processes where neovascular growth is a critical component. 
3. Experimental Section  
3.1. Animals, cell culture, and tumors 
Female C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) 6 to 8 weeks old were used in this 
study. The animal experiments were approved by the Institutional Animal Care and Use Committee at 
the University of North Carolina at Chapel Hill. 
Human blood outgrowth endothelial cells (HBOEC) were isolated from peripheral blood of 
consented volunteer donors and cultured as previously described [16,29]. Human umbilical vein 
endothelial cells (HUVEC) (Lonza, Walkersville, MD) were maintained in EGM-2 Bullet Kit medium 
(Lonza). Murine Lewis lung carcinoma (LLC) cells (ATCC, Manassas, VA) were grown in 
Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum. Murine 
bone marrow cells were collected by flushing femoral and tibial bones of black mice with 1 ml cold 
PBS containing 1 mM EDTA and 0.5% BSA. BM cells were used without further subpopulation 
enrichment procedures. 
To establish tumors, mice were anesthetized by intraperitoneal administration of Avertin  
(0.02 mL/g). LLC cells were trypsinized, washed three times in DMEM, counted and re-suspended in 
500 μL growth factor reduced Matrigel basement membrane matrix (BD Biosciences, Bedford, MA). 
Approximately 5 × 106 LLC cells were implanted subcutaneously in the inguinal region of each 




mouse. Controls included 500 μL Matrigel matrix without LLC cells. A control plug was implanted 
symmetrically to the LLC tumor in animals used for the final round of in vivo biopanning. 
3.2. Peptide library screening 
Combinatorial peptide library displayed on the N-terminus of the pIII minor coat protein of 
bacteriophage M13 was purchased from New England Biolabs (Beverly, MA). The library contains 
approximately 2.7 × 109 random 12-mer amino acid sequences. Tumor-associated peptide ligands were 
selected by a combination of in vitro and in vivo panning protocols. Briefly, for the in vitro selection  
1 × 1011 pfu of the original library were pre-cleared on HUVEC suspension for 2 h at 4 °C. The phage 
supernatant from the negative selection on HUVEC was incubated for 1 h at 4 °C with HBOEC 
suspension. Unbound phage pool was washed way, HBOEC-bound phage were eluted, amplified in E. 
Coli, and used for subsequent enrichment cycles as previously described [16]. After three rounds of 
biopanning on HBOEC, the enriched phage pool, designated as mini-library, was utilized for in vivo 
selection. Two selection schemes were designed and the experiments were conducted in parallel: (i) 
The mini-library (1 × 1011 pfu) was injected i.v. into the tail vein of a LLC tumor bearing mouse or (ii) 
The mini-library (1 × 1011 pfu) was used for labeling freshly isolated BM cells. Phage were allowed to 
bind to the BM cell suspension in EGM-2 containing 0.5% BSA for 1 h at RT. Unbound phage were 
washed way and BM-bound phage were administered i.v. in a LLC tumor bearing mouse. In both 
schemes, 2 hours post-phage injection the mice were perfused through the heart with PBS, the tumors 
harvested, and processed to elute the tumor-bound phage. Phage from each protocol were amplified 
separately in E. coli, and either were administered i.v. in a LLC tumor bearing mouse, or bound to BM 
cells and used for the next round of functional selection. The phage panning process was repeated three 
times for free phage and for BM-bound phage, respectively. All biopanning experiments were carried 
out 4 days post-tumor implantation. This time point was determined experimentally by monitoring the 
ability of subcutaneously implanted LLC tumors to recruit BM cells (data not shown). 
 
3.3. DNA sequencing 
 
For each in vivo screening procedure, fifty individual phage clones from the tumors and the control 
plugs were randomly picked and the peptide coding inserts were sequenced using -96III sequencing 
primer, 5’-GCCCTCATAGCGTAACG-3’, (New England Biolabs) following the manufacturer’s 
instructions. DNA sequencing was performed by the UNC-CH Genome Analysis Facility  
(Chapel Hill, NC).  
3.4. Peptide sequence analysis 
For homology identification the primary peptide sequences were analyzed using the Basic Local 
Alignment Search Tool (BLAST) services provided by NCBI [20]. Non redundant protein database 
(nr) searched with algorithm parameters adjusted for identification of short and nearly exact matches 
were utilized. Conserved Domain Database (CDD) was searched to find domains conserved across 
species [24]. The repository for phage derived peptides, MimoDB, was examined to check if the 
peptide sequences identified here have been found to bind to other targets [17]. 




3.5. Characterization of QFP-phage clone binding to LLC tumors 
 
The selectivity of QFP-phage towards LLC tumors and phage distribution in blood, liver and heart 
were analyzed using the same protocols and conditions as for the mini-library screening. 
 
3.6. Phage modification 
 
QFP-phage and control insertless phage were amplified to a high titer for labeling with 64Cu 
radionuclide via the macrocyclic bifunctional chelator 2-(4-isothiocyanatobenzyl)-1,4,7,10 tetraa-
zacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) (Macrocyclics, Dallas, TX). The 
isothiocyanate functionality of the p-SCN-Bn-DOTA reacts with primary amino groups on the phage 
coat protein pVIII to produce a covalent attachment of DOTA to the phage surface [30]. To carry out 
this functionalization procedure, phage (1 × 1011 pfu) were re-suspended in 400 μL conjugation buffer 
(carbonate-bicarbonate buffer, pH = 9) and 4 μL p-SCN-Bn-DOTA (100 mM stock) were added. The 
conjugation reaction was conducted overnight at 35 °C. DOTA-phage intermediate was separated from 
the unreacted DOTA through a 50 K microcone filter by centrifugation at 14,000g for 10 minutes. 
DOTA-phage conjugates were re-suspended in 400 μL 0.1M sodium acetate buffer (pH = 5.5) and 
incubated with 64CuCl2 (2 mCi per reaction, decay corrected) for 50 minutes at 50oC. Unbound 64Cu2+ 
was removed by ultracentrifugation as described above. 64Cu labeled phage were reconstituted in 
sterile PBS. Activity was determined using a γ-counter (Packard) immediately before injecting into 
mice. Complexes of DOTA-phage with cold CuCl2 were prepared to test phage infectivity and target 
binding upon labeling using protocols described above for chemically unmodified phage particles.  
 
3.7. MicroPET imaging  
 
MicroPET scans and image analysis were performed on a GE Explore Vista microPET/CT rodent 
scanner. At seven days post-implantation, mice bearing subcutaneous LLC tumors (tumor volume 
approx. 1 cm3) were injected with 800 μCi of radiotracer 64Cu – DOTA (n = 3), 64Cu –DOTA-control 
phage (n = 2) or 64Cu –DOTA-QFP-phage (n = 3) into the tail vein at a volume 150 μL. Ten minute 
microPET static scans were acquired 18 hours post-contrast injection under isoflurane anesthesia. 
Images were reconstructed and the radioactivity concentration within tumor and liver was converted 
into standard uptake values. Regions of interest (ROI) for the tumor were selected from the right lateral 
(actively perfused shell of the tumor), avoiding the (necrotic/lower intensity) regions. Location of the 
ROI within tumor margins was confirmed by comparison with the registered CT image. The liver ROI 
was selected in the uniform central region of the right lobe, placed away from the edges to avoid 
partial volume effect from the large voxel size in PET images.   
4. Conclusions  
Using a combination of in vitro and in vivo functional screening protocols we have isolated the 
QFPPKLTNNSML peptide that is selective for circulating bone marrow derived cells homing to 
angiogenic LLC tumors. We have demonstrated the ability of the QFPPKLTNNSML peptide to 




deliver molecular cargo to sites of ongoing angiogenesis by noninvasive PET imaging. The selection 
strategy we have described in this report can be easily extended to target other malignancies that 
recruit bone marrow derived cells to sustain growth of new blood vessels. 
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